COSTEM 2019 | BCMA-specific CAR-T cells for R/R multiple myeloma

Nicolaus Kröger

Nicolaus Kröger, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, evaluates the efficacy and safety of B-cell maturation antigen-specific (BCMA) CAR-T cells for relapsed/refractory multiple myeloma. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

Share this video  
Similar topics